Bone structure is an integral determinant of bone strength. The availability of high resolution peripheral quantitative computed tomography (HR-pQCT) has made it possible to measure three-dimensional bone microarchitecture and volumetric bone mineral density in vivo, with accuracy previously unachievable and with relatively low-dose radiation. Recent studies using this novel imaging tool have increased our understanding of age-related changes and sex differences in bone microarchitecture, as well as the effect of different pharmacological therapies. One advantage of this novel tool is the use of finite element analysis modelling to non-invasively estimate bone strength and predict fractures using reconstructed three-dimensional images. In this paper, we describe the strengths and limitations of HR-pQCT and review the clinical studies using this tool.
1 January 2009 in The Journal of Clinical Endocrinology & Metabolism
Context: Vitamin D insufficiency has now reached epidemic proportions and has been linked to low bone mineral density, increased risk of fracture, and obesity in adults. However, this relationship has not been well characterized in young adults. Objective: The objective of the study was to examine the relationship between serum 25-hydroxyvitamin D (25OHD), anthropometric measures, body fat (BF), and bone structure at the time of peak bone mass. Design: This was a cross-sectional study. Outcome Measures and Subjects: Anthropometric measures, serum 25OHD radioimmunoassay values, and computed tomography and dual-energy x-ray absorptiometry values of BF and bone structure in 90 postpubertal females, aged 16–22 yr, residing in California were measured. Results: Approximately 59% of subjects were 25OHD insufficient (≤29 ng/ml), and 41% were sufficient (≥30 ng/ml). Strong negative relationships were present between serum 25OHD and computed tomography measures of visceral and sc fat and dual-energy x-ray absorptiometry values of BF. In addition, weight, body mass, and imaging measures of adiposity at all sites were significantly lower in women with normal serum 25OHD concentrations than women with insufficient levels. In contrast, no relationship was observed between circulating 25OHD concentrations and measures of bone mineral density at any site. Unexpectedly, there was a positive correlation between 25OHD levels and height. Conclusions: We found that vitamin D insufficiency is associated with increased BF and decreased height but not changes in peak bone mass.
Exposure of quiescent bovine parathyroid cells to serum or a serum substitute caused an elevation in [3H] thymidine incorporation, followed by an increase in cell number. This was preceded by a rapid transient rise in c-myc and c-fos proto-oncogene mRNA levels. Alterations in the medium calcium concentration had no effect on the growth state of quiescent parathyroid cells. In addition, varying the medium calcium concentration did not influence either the time course or the degree of induction of proto-oncogene expression or the subsequent increase in [3H] thymidine uptake or proliferation of stimulated parathyroid cells. In contrast, when 1,25-dihydroxycholecalciferol was added with serum or serum substitute to quiescent parathyroid cells, no increase in c-myc mRNA levels was observed, and the expected increase in parathyroid cell number failed to occur. The augmentation in c-fos mRNA in response to serum was not, however, altered by 1,25-dihydroxycholecalciferol. These results indicate that 1,25-dihydroxyvitamin D, but not extracellular calcium, may directly modulate parathyroid cell proliferation by altering the expression of specific replication-associated oncogenes.